# Sermorelin Research: Mechanism, Trials & the GHRH(1-29) Evidence > Sermorelin research summarized: how GHRH(1-29) drives the pituitary, the pediatric and aging trials, the regenerative frontier, and how it compares to ipamorelin and tesamorelin. ## Before the details Sermorelin research splits cleanly into three buckets, and keeping them apart is the whole job. First, the solid stuff: it makes the pituitary release growth hormone, proven in children and in older men [1][2]. Second, the pharmacology: it works fast, clears fast, and lasts a few hours per dose [3]. Third, the frontier: animal and computer studies hinting at wound-healing and even cancer applications that have not been tested in people [8][9]. Below, each bucket gets its own section with the studies named and graded. The plain rule this page follows: a finding in a 1,018-patient computer screen and a finding in a randomized human trial are not the same kind of evidence, and they never get written as if they were. ## What is sermorelin Sermorelin (sermorelin acetate) is the amidated 29-amino-acid amino-terminal fragment of the body's 44-residue GHRH — GHRH(1-29), the shortest fragment that keeps full activity at the GHRH receptor [6]. Chemically it carries CAS 86168-78-7 and a molecular weight near 3,358 Da. It is not growth hormone; it is the signal that asks for growth hormone. That single distinction resolves most of the confusion in consumer write-ups: sermorelin cannot raise GH in someone whose pituitary cannot respond, and it works with, not around, the body's feedback system [4]. ## Sermorelin peptide: mechanism of action The sermorelin peptide binds the GHRH receptor (a class B G-protein-coupled receptor) on anterior-pituitary somatotrophs and activates Gs/adenylate cyclase/cAMP/protein kinase A signaling, which drives GH gene transcription and pulsatile GH release [6]. Downstream, GH prompts the liver to make IGF-1, which mediates many of GH's effects and feeds back to restrain further GH release [12]. Somatostatin provides the opposing brake. A study of GH autofeedback — modulated by free fatty acids and somatostatin — illustrates that these regulatory loops stay operative during GHRH-analog stimulation, which is the mechanistic basis for the "more physiologic" argument [12][4]. A 2025 Nature Reviews Endocrinology review synthesizes this signaling biology across health and disease [6]. ## The human trial record The pediatric trial is the anchor: once-daily subcutaneous GHRH(1-29) accelerated linear growth in prepubertal GH-deficient children, with first-year height velocity rising from about 4.1 to roughly 7-8 cm/year and no excessive IGF-1 generation [1]. The aging-research record is smaller and short-term: in healthy older men, 0.5 mg and 1 mg twice daily for 14 days raised 24-hour GH and IGF-1 dose-dependently, normalizing them toward young-adult values with no fasting-glucose effect [2]. Pharmacokinetic work in 30 healthy men established the dose-response (GH release from 0.25 mcg/kg IV) and the roughly three-hour GH elevation per dose [3]. The honest reading: the GH/IGF-1 pharmacology is well characterized; durable adult clinical outcomes are not, which is why an editorial cautioned that anti-aging use is "not yet ready for prime time" [5]. ## The regenerative-oncology frontier This is the lens this site leads with, and the one most distorted in marketing. GHRH agonist analogs MR-409 and MR-502 stimulated proliferation and survival of human dermal fibroblasts (skin cells) through MEK/ERK and PI3K/AKT pathways in an IGF-1-receptor-independent manner, and topical MR-409 accelerated, less-fibrotic wound closure in animals [8]. On the cardiac side, a GHRH agonist improved a mouse model of heart failure with preserved ejection fraction [10], and an earlier study targeted the GHRH receptor for repair after myocardial infarction [11]. The oncology signal is purely computational: a transcriptomic screen across 1,018 glioma patients ranked recurrent glioma as most sermorelin-sensitive in silico, a hypothesis-generating drug-repurposing result, not a clinical trial [9]. Graded plainly: preclinical regenerative signals are promising and early; the oncology signal is a computer prediction; neither is human evidence of benefit. ## Sermorelin vs ipamorelin Sermorelin and ipamorelin both raise GH, but through different doors. Sermorelin is a GHRH analog acting on the GHRH receptor [6]. Ipamorelin is a growth-hormone-releasing peptide (GHRP) acting on the ghrelin/GHS receptor — a separate pathway [6]. Researchers sometimes pair a GHRH analog with a GHRP precisely because the two mechanisms are complementary. The practical point for a skeptic: claims that conflate the two as interchangeable are mechanistically wrong, and head-to-head human efficacy data for either as an adult anti-aging therapy are limited. ## Sermorelin vs tesamorelin Tesamorelin is a stabilized GHRH analog, not native GHRH(1-29); its added stability gives it a longer action and a real human evidence base in body composition and cognition [7]. Much of the "sermorelin reduces body fat and sharpens cognition" copy online is actually borrowing the tesamorelin trial result — the randomized study that found favorable cognition (P=0.03), +117% IGF-1, and -7.4% body fat used tesamorelin at 1 mg/day for 20 weeks [7]. They share a receptor and a logic; they are not the same molecule, and their evidence does not transfer. Native GHRH(1-29)'s short ~10-12-minute half-life is the very reason longer-acting analogs were engineered [3]. --- An engineering-datasheet reading of the sermorelin record — every GHRH(1-29) figure logged to its study and stamped with an evidence grade, the proven pediatric trial kept apart from the borrowed tesamorelin numbers and both apart from the in-silico oncology and preclinical regenerative signals; no clinic behind the spec sheet and nothing here dosed, compounded, prescribed, or sold.